<DOC>
	<DOCNO>NCT01495702</DOCNO>
	<brief_summary>This study evaluate noninferiority Stribild® ( elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate ( E/C/F/TDF ) ) single-tablet regimen ( STR ) relative regimen consist nonnucleoside reverse transcriptase inhibitor ( NNRTI ) plus Truvada® ( FTC/TDF ) maintain HIV-1 RNA &lt; 50 copies/mL Week 48 virologically suppress , HIV-1 infect adult . This study also evaluate safety , tolerability , efficacy two regimens 96 week treatment .</brief_summary>
	<brief_title>Study Evaluate Switching From Regimens Consisting Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine Tenofovir DF Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen Virologically Suppressed , HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Ability understand sign write informed consent form Be stable current formulation ( ) antiretroviral regimen consist NNRTI plus FTC/TDF ≥ 6 consecutive month precede screen visit . This include begin regimen individual drug component subsequently simplify include fixeddose combination formulation drug . Be first second antiretroviral regimen document undetectable plasma HIV 1 RNA level ≥ 6 month precede screen visit No previous use approve experimental integrase strand transfer inhibitor ( INSTI ) length time Documented historical genotype prior start initial antiretroviral therapy show know resistance TDF FTC HIV RNA &lt; 50 copies/mL screen Normal ECG Hepatic transaminases ≤ 5 × upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL Adequate hematologic function Serum amylase ≤ 5 × ULN Estimated glomerular filtration rate ≥ 70 mL/min Females childbearing potential must agree utilize protocol recommend contraception method nonheterosexually active , practice sexual abstinence screen throughout duration study period 12 week participant EFV/FTC/TDF efavirenz 30 day rest participant follow last dose study drug Female participant utilize hormonal contraceptive one birth control method must use method least three month prior study dose Male participant must agree utilize protocolrecommended method contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence screen visit . Age ≥ 18 year New AIDSdefining condition diagnose within 30 day prior screen Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Receiving drug treatment hepatitis C , anticipate receive treatment hepatitis C course study Experiencing decompensated cirrhosis Have implant defibrillator pacemaker Current alcohol substance abuse would interfere compliance A history malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Persons cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline must anticipate require systemic therapy study . Active , serious infection require parenteral antibiotic antifungal therapy within 30 day prior baseline Have treat immunosuppressant therapy chemotherapeutic agent within 3 month study screening , expect receive agent systemic steroid study Receiving ongoing therapy medication , include drug use elvitegravir , cobicistat , FTC , TDF ; know allergy excipients E/C/F/TDF tablet , FTC/TDF tablets No anticipated need initiate drug study contraindicate Receiving investigational drug Participation clinical trial Any clinical condition prior therapy would make participant unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>